Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer

被引：2
作者：
Schwartz, Naomi R. M. [1 ]
DeBusk, Kendra [1 ]
Forero-Torres, Andres [1 ]
Feliciano, Joseph [1 ]
Anupindi, Vamshi Ruthwik [2 ]
Yeaw, Jason [2 ]
McBride, Ali [3 ,4 ]
机构：
[1] Seagen Inc, Bothell, WA 98021 USA
[2] IQVIA, Falls Church, VA 22042 USA
[3] Univ Arizona, Canc Ctr, Phoenix, AZ 85004 USA
[4] Univ Arizona, Coll Pharm, Phoenix, AZ 85004 USA
来源：
FUTURE ONCOLOGY | 2021年 / 17卷 / 26期
关键词：
central nervous system metastases; economic burden; healthcare costs; healthcare resource utilization; HER2-positive; metastatic breast cancer; BRAIN METASTASIS; TRASTUZUMAB; SURVIVAL; SUBTYPES; THERAPY; IMPACT;
D O I：
10.2217/fon-2020-1292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Compare healthcare resource utilization and costs among patients with HER2+ metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases. Methods: Retrospective matched cohort study using IQVIA's PharMetrics(R) Plus claims database. Results: Patients with CNS metastases (n = 753) experienced more outpatient, emergency room and inpatient visits versus controls (n = 753; all p < 0.05). In the post-index year, median total all-cause healthcare costs were significantly higher among patients with CNS metastases versus controls ($112,402 vs $50,835; p < 0.0001); outpatient costs primarily drove the cost differential. Conclusion: More effective therapies are needed that improve clinical outcomes and reduce economic burden associated with CNS metastases in patients with HER2+ MBC.
引用
收藏
页码：3457 / 3464
页数：8
相关论文
共 28 条
  • [1] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Bendell, JC
    Domchek, SM
    Burstein, HJ
    Harris, L
    Younger, J
    Kuter, I
    Bunnell, C
    Rue, M
    Gelman, R
    Winer, E
    [J]. CANCER, 2003, 97 (12) : 2972 - 2977
  • [2] Prognostic factors of brain metastases from breast cancer: Impact of targeted therapies
    Braccini, Antoine Laurent
    Azria, David
    Thezenas, Simon
    Romieu, Gilles
    Ferrero, Jean Marc
    Jacot, William
    [J]. BREAST, 2013, 22 (05) : 993 - 998
  • [3] Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies
    Brosnan, Evelyn M.
    Anders, Carey K.
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (09)
  • [4] Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
    Brufsky, Adam M.
    Mayer, Musa
    Rugo, Hope S.
    Kaufman, Peter A.
    Tan-Chiu, Elizabeth
    Tripathy, Debu
    Tudor, Iulia Cristina
    Wang, Lisa I.
    Brammer, Melissa G.
    Shing, Mona
    Yood, Marianne Ulcickas
    Yardley, Denise A.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (14) : 4834 - 4843
  • [5] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
    Cardoso, F.
    Senkus, E.
    Costa, A.
    Papadopoulos, E.
    Aapro, M.
    Andre, F.
    Harbeck, N.
    Aguilar Lopez, B.
    Barrios, C. H.
    Bergh, J.
    Biganzoli, L.
    Boers-Doers, C. B.
    Cardoso, M. J.
    Carey, L. A.
    Cortes, J.
    Curigliano, G.
    Dieras, V.
    El Saghir, N. S.
    Eniu, A.
    Fallowfield, L.
    Francis, P. A.
    Gelmon, K.
    Johnston, S. R. D.
    Kaufmann, B.
    Koppikar, S.
    Krop, I. E.
    Mayer, M.
    Nakigudde, G.
    Offersen, B. V.
    Ohno, S.
    Pagani, O.
    Paluch-Shimon, S.
    Penault-Llorca, F.
    Prat, A.
    Rugo, H. S.
    Sledge, G. W.
    Spence, D.
    Thomssen, C.
    Vorobiof, D. A.
    Xu, B.
    Norton, L.
    Winer, E. P.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (08) : 1634 - 1657
  • [6] Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
    Gabos, Zsolt
    Sinha, Richie
    Hanson, John
    Chauhan, Nitin
    Hugh, Judith
    Mackey, John R.
    Abdulkarim, Bassam
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) : 5658 - 5663
  • [7] Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Mason, Ginny
    Yardley, Denise A.
    Jahanzeb, Mohammad
    Brufsky, Adam
    Rugo, Hope S.
    Swain, Sandra M.
    Kaufman, Peter A.
    Tripathy, Debu
    Chu, Laura
    Li, Haocheng
    Antao, Vincent
    Cobleigh, Melody
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (08) : 2433 - 2441
  • [8] Patterns of breast cancer relapse in accordance to biological subtype
    Ignatov, Atanas
    Eggemann, Holm
    Burger, Elke
    Ignatov, Tanja
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1347 - 1355
  • [9] The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma
    Lai, R
    Dang, CT
    Malkin, MG
    Abrey, LE
    [J]. CANCER, 2004, 101 (04) : 810 - 816
  • [10] Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment
    Le Scodan, Romuald
    Massard, Christophe
    Jouanneau, Ludivine
    Coussy, Florence
    Gutierrez, Maya
    Kirova, Youlia
    Lerebours, Florence
    Labib, Alain
    Mouret-Fourme, Emmanuelle
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2012, 106 (01) : 169 - 176
123